A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine

Alm Site 1, Graz

Alm Site 2, Ghent

Alm Site 14, Bordeaux

Alm Site 17, Le Mans

Alm Site 19, Lille

Alm Site 20, Lille

Alm Site 13, Martigues

Alm Site 16, Nantes

Alm Site 15, Nice

Alm Site 18, Pierre-Bénite

Alm Site 12, Reims

Alm Site 28, Bad Bentheim

Alm Site 30, Berlin

Alm Site 24, Blankenfelde

Alm Site 32, Bonn

Alm Site 31, Frankfurt

Alm Site 27, Göttingen

Alm Site 26, Hamburg

Alm Site 29, Kiel

Alm Site 25, Marburg

Alm Site 34, Bergen op Zoom

Alm Site 33, Rotterdam

Alm Site 35, Utrecht

Alm Site 45, Bialystok

Alm Site 43, Chorzów

Alm Site 38, Katowice

Alm Site 41, Krakow

Alm Site 46, Krakow

Alm Site 37, Lodz

Alm Site 39, Lublin

Alm Site 48, Ostrowiec Świętokrzyski

Alm Site 44, Rzeszów

Alm Site 36, Szczecin

Alm Site 42, Warsaw

Alm Site 47, Warsaw

Alm Site 40, Wroclaw

Alm Site 10, Alicante

Alm Site 3, Badalona

Alm Site 6, Barcelona

Alm Site 8, Barcelona

Alm Site 4, Bilbao

Alm Site 5, Madrid

Alm Site 11, Mieres

Alm Site 7, Seville

Alm Site 9, Zaragoza

Alm Site 23, Poole

Alm Site 22, Salford

Alm Site 21, Southampton